S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
Log in
NASDAQ:KOD

Kodiak Sciences Stock Forecast, Price & News

$158.60
-5.87 (-3.57 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$158.53
Now: $158.60
$168.96
50-Day Range
$134.79
MA: $149.58
$164.47
52-Week Range
$35.49
Now: $158.60
$169.98
Volume272,278 shs
Average Volume275,523 shs
Market Capitalization$7.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

432nd out of 1,928 stocks

Biological Products, Except Diagnostic Industry

58th out of 177 stocks

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KOD
CUSIPN/A
CIKN/A
Phone650 281 0850
Employees62

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$9.32 per share

Profitability

Net Income$-47,370,000.00

Miscellaneous

Market Cap$7.11 billion
Next Earnings Date3/15/2021 (Estimated)
OptionableOptionable
$158.60
-5.87 (-3.57 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KOD News and Ratings via Email

Sign-up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kodiak Sciences (NASDAQ:KOD) Frequently Asked Questions

How has Kodiak Sciences' stock been impacted by COVID-19?

Kodiak Sciences' stock was trading at $53.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KOD shares have increased by 194.5% and is now trading at $158.60.
View which stocks have been most impacted by COVID-19
.

Is Kodiak Sciences a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kodiak Sciences stock.
View analyst ratings for Kodiak Sciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Kodiak Sciences?

Wall Street analysts have given Kodiak Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kodiak Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Kodiak Sciences' CEO?

1,428 employees have rated Kodiak Sciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Kodiak Sciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Kodiak Sciences' next earnings date?

Kodiak Sciences is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Kodiak Sciences
.

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NASDAQ:KOD) issued its earnings results on Monday, November, 9th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.13.
View Kodiak Sciences' earnings history
.

What price target have analysts set for KOD?

12 Wall Street analysts have issued 12-month price targets for Kodiak Sciences' shares. Their forecasts range from $69.00 to $170.00. On average, they expect Kodiak Sciences' share price to reach $125.91 in the next year. This suggests that the stock has a possible downside of 20.6%.
View analysts' price targets for Kodiak Sciences
or view Wall Street analyst' top-rated stocks.

Who are some of Kodiak Sciences' key competitors?

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and Axon Enterprise (AAXN).

Who are Kodiak Sciences' key executives?

Kodiak Sciences' management team includes the following people:
  • Dr. Victor Perlroth, Chairman, MD, CEO & Pres (Age 47, Pay $927.76k)
  • Mr. John A. Borgeson CPA, M.B.A., MBA, CPA, Sr. VP, CFO & Sec. (Age 58, Pay $635.88k)
  • Dr. Jason S. Ehrlich M.D., Ph.D., Chief Medical Officer & Chief Devel. Officer (Age 44, Pay $777.46k)
  • Dr. Hong Liang, Sr. VP of Discovery Medicine (Age 48)
  • Ms. Almas Qudrat M.Sc., Sr. VP of Quality Operations

When did Kodiak Sciences IPO?

(KOD) raised $126 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers.

What is Kodiak Sciences' stock symbol?

Kodiak Sciences trades on the NASDAQ under the ticker symbol "KOD."

Who are Kodiak Sciences' major shareholders?

Kodiak Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include First Midwest Bank Trust Division (0.02%) and Pacer Advisors Inc. (0.00%). Company insiders that own Kodiak Sciences stock include Bros Advisors Lp Baker, Hong Liang, Jason Ehrlich and Richard S Levy.
View institutional ownership trends for Kodiak Sciences
.

Which institutional investors are selling Kodiak Sciences stock?

KOD stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and Pacer Advisors Inc.. Company insiders that have sold Kodiak Sciences company stock in the last year include Hong Liang, and Jason Ehrlich.
View insider buying and selling activity for Kodiak Sciences
or view top insider-selling stocks.

How do I buy shares of Kodiak Sciences?

Shares of KOD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kodiak Sciences' stock price today?

One share of KOD stock can currently be purchased for approximately $158.60.

How big of a company is Kodiak Sciences?

Kodiak Sciences has a market capitalization of $7.11 billion. The company earns $-47,370,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Kodiak Sciences employs 62 workers across the globe.

What is Kodiak Sciences' official website?

The official website for Kodiak Sciences is kodiak.com.

How can I contact Kodiak Sciences?

Kodiak Sciences' mailing address is 2631 HANOVER STREET, PALO ALTO CA, 94304. The company can be reached via phone at 650 281 0850 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.